Interestingly, tamoxifen and ICI endocrine-resistant BC cells showed the same responses to DOT1L blockade both in vitro and in vivo, pointing out DOT1L as a new target in hormone-responsive and endocrine-resistant BC. This evidence concerns the gene DOT1L and breast cancer.